Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAR Polypill in Alzheimer's Disease
NCT06597058Phase 2Completed
- Sponsor
- Noah Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MAR COMBO with MAR PLACEBO (2 arms). Primary endpoints: Clinical Dementia Rating - Global at 210 days, Clinical Dementia Rating - Sum of Boxes at 210 days and 8 more. Started Oct 2024; status: completed.
02
Drugs
MAR
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06597058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597058.